Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149799 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00149799: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00149799 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00149799, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
Primary Outcome
We compared the rate of relapse (accounting for time from randomization to relapse and censoring) by treatment arm in Phase II.
Interventions
- DRUG Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
What the finished NCT00149799 record still lists
NCT00149799 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00149799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00149799 about?
NCT00149799 is a clinical study titled "Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder". This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
What is the current status of trial NCT00149799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2005-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00149799?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00149799?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00149799's enrollment target sits among peer trials
100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia